Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Association of RB1 mutational status with overall genomic landscape in NEPC

Petros Grivas • 19 Feb 2022
GU Cancers 2022
Genitourinary Cancer Prostate Cancer

Petros Grivas, MD, PhD, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, provides an overview of a study evaluating the association of RB1 mutational status with overall genomic landscape in patients with neuroendocrine prostate cancer (NEPC). This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Petros Grivas

1:08
Phase III clinical trials exploring targeted combination therapies for patients with UC
Petros Grivas • 20 Oct 2023
1:39
Phase Ib trial of bintrafusp alfa for advanced urothelial cancer
Petros Grivas • 20 Oct 2023
2:21
How junior physicians can develop a successful career in medical oncology
Petros Grivas • 20 Oct 2023
1:54
Innovations in treatment options for patients with BCG-unresponsive urothelial carcinoma
Petros Grivas • 20 Oct 2023

Related Videos

3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals